Bone Density Negatively Impacted by ADHD Drugs
Drug Topics
OCTOBER 14, 2022
Recent research determined the psychostimulants modafinil, atomoxetine, and guanfacine negatively impact bones.
Drug Topics
OCTOBER 14, 2022
Recent research determined the psychostimulants modafinil, atomoxetine, and guanfacine negatively impact bones.
PharmaVoice
OCTOBER 14, 2022
Pharma industry leaders share their brand personas.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 14, 2022
Your weekly roundup of the latest news from Drug Topics®.
Pharmacy Times
OCTOBER 14, 2022
A presentation at the AMCP Nexus conference focuses on the health care disparities and pharmacotherapy options for gender affirmation.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
OCTOBER 14, 2022
Share your thoughts on this year in review.
Pharmacy Times
OCTOBER 14, 2022
Presenters at the AMCP Nexus conference explore outcomes data and whether these medications should be substituted for reference products more frequently.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
OCTOBER 14, 2022
At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.
pharmaphorum
OCTOBER 14, 2022
A consortium of industry and academic groups – led by Johnson & Johnson’s pharma division Janssen – has been set up to tackle the environmental impact of digital health products, specifically aimed at minimising waste that could end up in landfill. The Digital Health in a Circular Economy (DiCE) group was formed earlier this year with the aim of developing ways to “design, collect, directly reuse, refurbish, remanufacture, and recycle digital health devices.” The programme
Pharmacy Times
OCTOBER 14, 2022
New treatments for chronic migraine have been increasing, with robust evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxin A.
European Pharmaceutical Review
OCTOBER 14, 2022
RemeGen has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its proprietary novel fusion protein Telitacicept (RC18) for the treatment of myasthenia gravis (MG). Telitacicept is a proprietary novel fusion protein from RemeGen to treat autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallisable
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 14, 2022
Research indicates quadruplet regimens may be a viable option for this disease.
Pharmaceutical Technology
OCTOBER 14, 2022
German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs. They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.
Pharmacy Times
OCTOBER 14, 2022
As a part of the Women in Pharmacy series, Vibhuti Arya, PharmD, MPH, FAPhA, global lead, Gender Equity and Diversity Workforce Development at FIP, discusses moments that shaped her vision for her career in pharmacy.
STAT
OCTOBER 14, 2022
In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the country already awash in prescription painkillers, the federal government was demanding accountability from the pharmacy giant for filling thousands of opioid prescriptions written by doctors in suspiciously large quantities. Scrambling for a solution, the company’s leadership traded ideas for new ways of ensuring its pharmacies would stop filling medically illegitimate prescriptions.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 14, 2022
The process of supporting a cause for our profession can be highly rewarding. As pharmacists, we must take charge to enact change.
pharmaphorum
OCTOBER 14, 2022
Biotech company Odyssey Therapeutics, Inc. has announced a $168 million Series B financing, led by global venture capital firm General Catalyst, an active investor in the healthcare sector. The proceeds are to advance Odyssey’s precision immunomodulator and oncology medicine portfolio. The latest funding announcement follows the company’s $218 million Series A financing in December 2021 and brings the total capital raised to $386 million – enabling continuance of Odyssey’s mission to devel
Pharmacy Times
OCTOBER 14, 2022
Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.
STAT
OCTOBER 14, 2022
Forty years ago, in his Pulitzer Prize-winning history “The Social Transformation of American Medicine,” sociologist Paul Starr predicted that independent physician practice, which had been a cornerstone of American medicine for most of the 20th century, would be eclipsed by the “coming of the corporation.” Starr forecast that the end of the century would not only be “a time of diminishing resources and autonomy” of this powerful profession, but a
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
OCTOBER 14, 2022
Investigators found that lifestyle changes such as a high-quality diet and regular exercise can lower the risk of type 2 diabetes in women with a history of gestational diabetes mellitus.
STAT
OCTOBER 14, 2022
A group of Republican senators is demanding to know what steps the U.S. National Institutes of Health will take to ensure that results of clinical trials funded by the agency — both those conducted by its own scientists and outside researchers — are reported to a federal database. In a letter sent on Thursday to NIH Acting Director Lawrence Tabak, the lawmakers cited a recent report showing the agency failed to conduct proper follow-up.
pharmaphorum
OCTOBER 14, 2022
Day 3 coverage: Click here to read Reuters: Pharma 2022 Day 1 overview. Click here or the image below to read Reuters: Pharma 2022 Day 2 coverage. The post Reuters Pharma 2022 – Day 3 coverage appeared first on.
STAT
OCTOBER 14, 2022
Insurance giant UnitedHealth Group’s strong financial showing in the third quarter was driven in part by its fast-growing provider segment, Optum Health. UnitedHealth’s network of outpatient clinics and roughly 60,000 doctors is already more profitable than the company’s larger insurance division, UnitedHealthcare. UnitedHealth’s CEO outlined the company’s plans to expand Optum Health’s reach even further on an investor call Friday.
Digital Pharmacist
OCTOBER 14, 2022
Pharmacy Week is almost here and what an exciting time is it! Pharmacy Week takes place during the 3 rd week of October each year. According to ASHP, this week is “a time to recognize the powerful impact you make on your patients”. No better time to celebrate your pharmacy teams and their impact as well as your incredible patients than Pharmacy Week. .
STAT
OCTOBER 14, 2022
When Hurricane Fiona knocked out power across the entire island of Puerto Rico, hospitals turned to diesel-fueled generators to keep the lights on and critical machines running. Community health centers — often the most accessible medical facilities in the poorest districts of the island, those hardest hit by hurricanes — couldn’t immediately do the same.
Pharmaceutical Commerce
OCTOBER 14, 2022
How to navigate the ongoing temperature challenges surrounding storage & distribution.
STAT
OCTOBER 14, 2022
Amid rising concern over antibiotic resistance, a new report finds that a dozen of the leading grocery chains in the U.S. are largely failing to take steps that are needed to prevent the spread of so-called superbugs in the food supply chain. In general, most of the companies lack any meaningful policies requiring their meat and poultry suppliers to eliminate the overuse of antibiotics.
European Pharmaceutical Review
OCTOBER 14, 2022
Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. The data demonstrated that uptake in the US continues to grow and has created a large market share in most therapeutic areas where biosimilars have been launched.
STAT
OCTOBER 14, 2022
With health emergencies becoming more common, the world needs more efficient ways to test the safety and effectiveness of drugs, even if they haven’t yet completed the lengthy series of clinical trials the Food and Drug Administration usually requires. Data from the real-world use of new drugs offers an increasingly valuable and efficient way to do this.
Pharmacy Times
OCTOBER 14, 2022
Presentation at the AMCP Nexus conference focuses on midterm election outlook and a plug for the Pre-approval Information Exchange Act.
pharmaphorum
OCTOBER 14, 2022
In this article, Research Partnership reviews why the path to commercialisation for the half a dozen approvals in Europe over the last few years has not been smooth, and shares feedback gathered from our payer network on the outlook for gene therapy market access in Europe, especially considering the shift to more prevalent diseases. In January, the Alliance for Regenerative Medicine (ARM)’s Cell and Gene State of the Industry briefing earmarked 2022 as a record year for approval of gene therapi
STAT
OCTOBER 14, 2022
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Pharmacy Times
OCTOBER 14, 2022
As part of American Pharmacist Month, Pharmacy Times is asking experts what they believe the value of the pharmacist is.
Pharma Times
OCTOBER 14, 2022
Research has demonstrated a strong safety prolife and reduced tics among participants
Let's personalize your content